GLP-1s and Vision Loss: What Prescribers Should Know About the Emerging NAION Signal

GLP-1 receptor agonists have transformed type 2 diabetes and obesity treatment, but a rare vision safety signal deserves clinicians’ attention. Emerging evidence has raised concerns about a potential NAION risk with GLP-1 therapy, particularly with semaglutide (Ozempic, Rybelsus, and Wegovy). Non-arteritic anterior ischemic optic neuropathy (NAION) can cause sudden, usually painless vision loss and may leave permanent impairment. Although the absolute risk appears low, recent observational studies and regulatory reviews make this an important counseling issue for prescribers.

Table of Contents

• What NAION is and why diabetes matters
• Evidence behind the semaglutide NAION signal
• Which patients may face greater risk
• Counseling, monitoring, and referral considerations
• Conclusion
• Frequently asked questions

What Is NAION and Why Does It Matter in Diabetes Care?

NAION occurs when blood flow to part of the optic nerve becomes inadequate, resulting in ischemic injury. Patients typically notice sudden, painless loss or worsening of vision in one eye. Unlike diabetic retinopathy, NAION primarily affects the optic nerve rather than the retinal blood vessels. Therefore, clinicians should not assume that sudden vision changes in a person with diabetes represent progression of retinopathy.

Importantly, diabetes itself is a recognized risk factor for NAION. Other established or suspected risk factors include older age, hypertension, dyslipidemia, smoking, obstructive sleep apnea, and certain optic nerve anatomy. Consequently, many patients who qualify for GLP-1 therapy already have several characteristics associated with NAION.

The distinction from diabetic retinopathy is especially important because potent glucose-lowering therapy can raise separate retinal monitoring questions. Diabetes in Control has previously reviewed rapid A1C reduction and diabetic retinopathy. NAION represents a different clinical problem and requires urgent ophthalmic evaluation when suspected.

What Does the Evidence Say About GLP-1s and NAION Risk?

Interest in a possible link between GLP-1 therapy and NAION increased substantially after a 2024 JAMA Ophthalmology study examined patients prescribed semaglutide. In the diabetes cohort, semaglutide exposure was associated with a higher NAION risk than non-GLP-1 medications. However, the study came from a neuro-ophthalmology practice, involved relatively few events, and was observational. Therefore, it identified an association rather than proving that semaglutide caused NAION.

Subsequent research has added weight to the signal while also highlighting uncertainty. A much larger 2025 cohort study involving more than 3.3 million patients with diabetes found an elevated NAION risk associated with semaglutide at several follow-up points. Yet, the investigators again emphasized that retrospective observational data cannot establish causality.

More recently, a nationwide study of U.S. veterans with type 2 diabetes compared semaglutide initiators with patients starting SGLT2 inhibitors. Semaglutide initiators had roughly twice the relative risk of NAION, although the absolute event rate remained low.

A 2025 systematic review and meta-analysis also found a statistical association between semaglutide and NAION. However, events were uncommon and the confidence interval was wide, leaving substantial uncertainty around the magnitude of risk.

Regulators have responded accordingly. The U.S. Food and Drug Administration identified NAION as a potential safety signal for the GLP-1 receptor agonist class and reported that it was evaluating whether regulatory action was needed.

Meanwhile, the European Medicines Agency reached a more specific conclusion in June 2025. After reviewing clinical trials, epidemiological studies, postmarketing surveillance, and other evidence, its safety committee classified NAION as a “very rare” adverse effect of semaglutide, potentially affecting up to 1 in 10,000 treated patients. The EMA estimated approximately one additional NAION case per 10,000 person-years of semaglutide treatment in adults with type 2 diabetes.

Who May Be Most Vulnerable to Semaglutide-Related Vision Loss?

The emerging NAION safety signal with semaglutide should be interpreted in the context of each patient’s baseline vascular and ocular health. Diabetes, hypertension, dyslipidemia, smoking, and obstructive sleep apnea can already increase vulnerability to optic nerve ischemia. Age and optic disc anatomy may add further risk.

Still, current evidence does not support withholding GLP-1 therapy from every patient with these characteristics. Semaglutide provides meaningful glycemic, weight, cardiovascular, and kidney benefits for appropriately selected patients. Diabetes in Control has also reviewed the broader cardiovascular benefits of GLP-1 receptor agonists.

Instead, clinicians can incorporate the potential signal into shared decision-making. A history of NAION, significant eye disease, or multiple vascular risk factors may justify a more individualized discussion and coordination with ophthalmology. Moreover, prescribers should distinguish concerns about NAION from the separate issue of diabetic retinopathy associated with rapid glycemic improvement.

Counseling Patients About NAION Risk With GLP-1 Therapy

Patient counseling does not need to create unnecessary alarm. Instead, patients should understand that NAION appears to be rare but that sudden vision changes require prompt action. Specifically, advise patients taking semaglutide to report sudden vision loss or rapidly worsening eyesight immediately.

Prescribers should treat these symptoms as urgent rather than waiting for the next routine diabetes visit. Rapid ophthalmology or neuro-ophthalmology assessment can help distinguish NAION from retinal vascular occlusion, retinal detachment, diabetic eye disease, or other causes of acute visual loss.

The European Medicines Agency recommends that patients experiencing sudden loss of vision or rapidly worsening eyesight while taking semaglutide contact a clinician without delay. Furthermore, if NAION is confirmed, EMA recommends stopping semaglutide treatment.

Routine diabetes care remains important as well. Blood pressure, glucose, lipid levels, smoking status, sleep apnea, and recommended eye examinations should all be addressed. As evidence evolves, clinicians should continue reviewing regulatory updates rather than assuming that the signal applies equally to every GLP-1 receptor agonist.

Conclusion

The emerging association between semaglutide and NAION represents an important but uncommon safety consideration. Observational studies, trial analyses, and regulatory surveillance increasingly support an association between semaglutide and NAION, while the absolute risk remains low and causality is still being clarified.

For prescribers, the practical message is straightforward. Continue weighing the substantial metabolic and cardiovascular benefits of GLP-1 therapy against individual patient risks, educate patients about sudden vision symptoms, and arrange urgent ophthalmic evaluation when those symptoms occur. Careful counseling can address the emerging signal without unnecessarily limiting access to an effective treatment.

Frequently Asked Questions

What is NAION?

NAION is an ischemic injury to the optic nerve caused by inadequate blood flow. It usually presents as sudden, painless vision loss and can result in permanent visual impairment.

Does semaglutide cause NAION?

Research shows an association, but observational studies cannot by themselves prove causation. However, the European Medicines Agency concluded in 2025 that NAION should be classified as a very rare adverse effect of semaglutide.

How common is NAION in patients taking GLP-1 medications?

The absolute risk appears small. The EMA estimated roughly one additional NAION case per 10,000 person-years of semaglutide treatment among adults with type 2 diabetes. Importantly, available evidence is strongest for semaglutide, so the findings should not automatically be assumed to apply equally to every GLP-1 receptor agonist.

Should patients stop semaglutide because of the NAION signal?

Patients should not stop prescribed therapy solely because they are concerned about published reports. Treatment decisions require an individualized benefit-risk discussion with a healthcare professional. However, sudden vision loss or rapidly worsening eyesight warrants urgent medical evaluation, and the EMA recommends discontinuing semaglutide if NAION is confirmed.

Is NAION the same as diabetic retinopathy?

No. Diabetic retinopathy primarily damages retinal blood vessels, while NAION involves ischemic injury to the optic nerve. Both can threaten vision, but their mechanisms and clinical management differ.

This content is not medical advice. For any health issues, always consult a healthcare professional. In an emergency, call 911 or your local emergency services.